In Europe, biosimilar uptake has been slow but is starting to ramp. An acceptance of biosimilars both in the U.S. and in Europe could present cost savings for patients, though these drugs are usually priced much higher than typical generic drugs.
In Europe, biosimilar uptake has been slow but is starting to ramp. An acceptance of biosimilars both in the U.S. and in Europe could present cost savings for patients, though these drugs are usually priced much higher than typical generic drugs.